Afficher la notice abrégée

Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008-2015)

dc.rights.licenseopenen_US
dc.contributor.authorSABATE, M.
dc.contributor.authorVIDAL, X.
dc.contributor.authorBALLARIN, E.
dc.contributor.authorROTTENKOLBER, M.
dc.contributor.authorSCHMIEDL, S.
dc.contributor.authorGRAVE, B.
dc.contributor.authorHUERTA, C.
dc.contributor.authorMARTIN-MERINO, E.
dc.contributor.authorMONTERO, D.
dc.contributor.authorLEON-MUNOZ, L. M.
dc.contributor.authorGASSE, C.
dc.contributor.authorMOORE, Nicholas
dc.contributor.authorDROZ, C.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLASSALLE, Regis
dc.contributor.authorAAKJAER, M.
dc.contributor.authorANDERSEN, M.
dc.contributor.authorDE BRUIN, M. L.
dc.contributor.authorSOUVEREIN, P.
dc.contributor.authorKLUNGEL, O. H.
dc.contributor.authorGARDARSDOTTIR, H.
dc.contributor.authorIBANEZ, L.
dc.date.accessioned2022-01-17T10:09:20Z
dc.date.available2022-01-17T10:09:20Z
dc.date.issued2021-11-03
dc.identifier.issn1663-9812 (Print) 1663-9812 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/124403
dc.description.abstractEnAims: To describe and compare the adherence to different direct oral anticoagulants (DOACs) in eight European databases representing six countries. Methods: Longitudinal drug utilization study of new users (≥18 years) of DOACs (dabigatran, rivaroxaban, apixaban) with a diagnosis of non-valvular atrial fibrillation (2008-2015). Adherence was examined by estimating persistence, switching, and discontinuation rates at 12 months. Primary non-adherence was estimated in BIFAP and SIDIAP databases. Results: The highest persistence rate was seen for apixaban in the CPRD database (81%) and the lowest for dabigatran in the Mondriaan database (22%). The switching rate for all DOACs ranged from 2.4 to 13.1% (Mondriaan and EGB databases, respectively). Dabigatran had the highest switching rate from 5.0 to 20.0% (Mondriaan and EGB databases, respectively). The discontinuation rate for all DOACs ranged from 16.0 to 63.9% (CPRD and Bavarian CD databases, respectively). Dabigatran had the highest rate of discontinuers, except in the Bavarian CD and AOK NORDWEST databases, ranging from 23.2 to 64.6% (CPRD and Mondriaan databases, respectively). Combined primary non-adherence for examined DOACs was 11.1% in BIFAP and 14.0% in SIDIAP. There were differences in population coverage and in the type of drug data source among the databases. Conclusion: Despite the differences in the characteristics of the databases and in demographic and baseline characteristics of the included population that could explain some of the observed discrepancies, we can observe a similar pattern throughout the databases. Apixaban was the DOAC with the highest persistence. Dabigatran had the highest proportion of discontinuers and switchers at 12 months in most databases (EMA/2015/27/PH).
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enAdherence
dc.subject.enPersistence
dc.subject.enAnticoagulants
dc.subject.enNon valvular atrial fibrillation
dc.subject.enCardiovascular
dc.subject.enDrug utilization
dc.subject.enPharmacoepidemiology
dc.subject.enEurope
dc.title.enAdherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008-2015)
dc.typeArticle de revueen_US
dc.identifier.doi10.3389/fphar.2021.682890en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34803665en_US
bordeaux.journalFrontiers in Pharmacologyen_US
bordeaux.page682890en_US
bordeaux.volume12en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDEuropean Medicines Agencyen_US
hal.identifierhal-03528331
hal.version1
hal.date.transferred2022-01-17T10:09:24Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers%20in%20Pharmacology&rft.date=2021-11-03&rft.volume=12&rft.spage=682890&rft.epage=682890&rft.eissn=1663-9812%20(Print)%201663-9812%20(Linking)&rft.issn=1663-9812%20(Print)%201663-9812%20(Linking)&rft.au=SABATE,%20M.&VIDAL,%20X.&BALLARIN,%20E.&ROTTENKOLBER,%20M.&SCHMIEDL,%20S.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_FP_2021_Sabate.pdf
Taille:
1.332Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée